search
Back to results

Evaluation of the Efficacy in Decreasing Myopia Progression of the Proposed Ophthalmic Lens Prototypes

Primary Purpose

Myopia

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Myopia control lens
Sponsored by
Indizen Optical Technologies, S.L.U.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Myopia

Eligibility Criteria

5 Years - 12 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age: 5 to 12 years old
  • Myopia (spherical equivalent with cycloplegic) ≤ -0.50D
  • Astigmatism < 1.50D
  • Anisometropia < 1.50D
  • Best-corrected visual acuity ≥ 20/20

Exclusion Criteria:

  • Patients who have received any previous treatment for myopia control, including the use of RPG contact lenses.
  • Participants with ocular pathology such as retinal detachment.
  • Participants using drugs that may affect pupillary size and accommodation or that produce effects on the ocular surface.
  • Participants with systemic diseases that may affect vision.

Sites / Locations

  • Universidad Europea of MadridRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Myopia Control Lens

Arm Description

Outcomes

Primary Outcome Measures

Axial length
Measure of axial length with a biometer
Refraction
Binocular refraction with autorefractometer under cyclopegia

Secondary Outcome Measures

Full Information

First Posted
February 3, 2022
Last Updated
February 17, 2022
Sponsor
Indizen Optical Technologies, S.L.U.
Collaborators
Universidad Europea de Madrid
search

1. Study Identification

Unique Protocol Identification Number
NCT05250206
Brief Title
Evaluation of the Efficacy in Decreasing Myopia Progression of the Proposed Ophthalmic Lens Prototypes
Official Title
Evaluation of Ophthalmic Lenses for Myopia Management
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 7, 2021 (Actual)
Primary Completion Date
June 7, 2022 (Anticipated)
Study Completion Date
June 7, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Indizen Optical Technologies, S.L.U.
Collaborators
Universidad Europea de Madrid

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Evaluation of the efficacy in decreasing myopia progression of the proposed ophthalmic lens prototypes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myopia

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Myopia Control Lens
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
Myopia control lens
Intervention Description
Evaluation of the efficacy in decreasing myopia progression of the proposed ophthalmic lens prototypes.
Primary Outcome Measure Information:
Title
Axial length
Description
Measure of axial length with a biometer
Time Frame
5 minutes
Title
Refraction
Description
Binocular refraction with autorefractometer under cyclopegia
Time Frame
5 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age: 5 to 12 years old Myopia (spherical equivalent with cycloplegic) ≤ -0.50D Astigmatism < 1.50D Anisometropia < 1.50D Best-corrected visual acuity ≥ 20/20 Exclusion Criteria: Patients who have received any previous treatment for myopia control, including the use of RPG contact lenses. Participants with ocular pathology such as retinal detachment. Participants using drugs that may affect pupillary size and accommodation or that produce effects on the ocular surface. Participants with systemic diseases that may affect vision.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Eva Chamorro, Phd
Phone
+34 (91) 833 37 86
Email
evachamorro@iot.es
Facility Information:
Facility Name
Universidad Europea of Madrid
City
Madrid
ZIP/Postal Code
28670
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
César Villa, Phd
Phone
914111111
Email
villacollarc@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
25270192
Citation
Hasebe S, Jun J, Varnas SR. Myopia control with positively aspherized progressive addition lenses: a 2-year, multicenter, randomized, controlled trial. Invest Ophthalmol Vis Sci. 2014 Sep 30;55(11):7177-88. doi: 10.1167/iovs.12-11462.
Results Reference
background
PubMed Identifier
30083910
Citation
Kanda H, Oshika T, Hiraoka T, Hasebe S, Ohno-Matsui K, Ishiko S, Hieda O, Torii H, Varnas SR, Fujikado T. Effect of spectacle lenses designed to reduce relative peripheral hyperopia on myopia progression in Japanese children: a 2-year multicenter randomized controlled trial. Jpn J Ophthalmol. 2018 Sep;62(5):537-543. doi: 10.1007/s10384-018-0616-3. Epub 2018 Aug 6.
Results Reference
background
PubMed Identifier
22559900
Citation
Morgan IG, Ohno-Matsui K, Saw SM. Myopia. Lancet. 2012 May 5;379(9827):1739-48. doi: 10.1016/S0140-6736(12)60272-4.
Results Reference
background

Learn more about this trial

Evaluation of the Efficacy in Decreasing Myopia Progression of the Proposed Ophthalmic Lens Prototypes

We'll reach out to this number within 24 hrs